DERMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Journey Medical Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$5.17+0.21 (+4.13%)
Close on Oct 19, 2026
- Market cap
- $142.14M
- P/E (TTM)
- –
- Dividend yield
- –
Journey Medical Corp revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Emrosi | $8.07M | $6.25M | $5.00M | $4.88M | $2.80M | $2.07M | – | – | – | – | – | – | 43.6% | +188.9% |
| Qbrexza | $5.11M | $5.03M | $5.54M | $7.36M | $6.95M | $5.16M | $5.68M | $7.58M | $6.84M | $5.02M | $7.37M | $5.87M | 27.6% | -26.4% |
| Accutane | $3.36M | $3.31M | $3.06M | $2.77M | $3.40M | $3.66M | $3.87M | $4.00M | $5.72M | $5.82M | $5.06M | $4.88M | 18.1% | -1.1% |
| Foam franchise products (Amzeeq & Zilxi) | $941.00K | $1.05M | $1.89M | $1.31M | $1.14M | $1.53M | $1.95M | $2.10M | – | – | – | – | 5.1% | -17.1% |
| Other / legacy | $232.00K | $277.00K | $575.00K | $701.00K | $735.00K | $727.00K | $1.12M | $950.00K | $726.00K | $1.17M | $1.13M | $1.52M | 1.3% | -68.4% |
| Eurax | $120.00K | – | – | – | – | – | – | – | – | – | – | – | 0.6% | – |
| Zilxi | – | – | – | – | $256.00K | $426.00K | $443.00K | $558.00K | $369.00K | $273.00K | $395.00K | $681.00K | – | – |
| Amzeeq | – | – | – | – | $879.00K | $1.10M | $1.51M | $1.54M | $1.21M | $755.00K | $1.30M | $2.34M | – | – |
By region
From the segment and revenue-disaggregation notes of Journey Medical's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.